PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133800 / 8360891 Sample Receive Date : 07/Nov/2023 12:45PM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 07/Nov/2023 04:39PM

HAEMATOLOGY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Glycosylated Hemoglobin (HbA1c) 5.8 % 4-5.6 HPLC

Estimated average glucose (eAG) 119.76 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

Page 1 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133800 / 8360891 Sample Receive Date : 07/Nov/2023 12:45PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 07/Nov/2023 03:19PM

HAEMATOLOGY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 12.7 g/dL 13.0-17.0 Cyanide free SLS
RBC 4.42 mili/cu.mm 4.5 - 5.5 Impedence variation
HCT 37.2 % 40 - 50 Calculated
MCV 84.2 fl 83 - 101 RBC Pulse Measurement
MCH 28.8 pg 27 - 32 Calculated
MCHC 34.2 g/dL 31.5 - 34.5 Calculated
RDW-CV 12.7 % 11.6-14 Calculated
Total Leucocyte Count 4.48 10^3/µI 4 - 10 Flowcytometry DHSS/
Microscopy
Differential Leucocyte Count
Neutrophils 54 % 40-80 Flowcytometry DHSS/
Microscopy
Lymphocytes 33 % 20-40 Flowcytometry DHSS/
Microscopy
Monocytes 09 % 2-10 Flowcytometry DHSS/
Microscopy
Eosinophils 04 % 1-6 Flowcytometry DHSS/
Microscopy
Basophils 00 % 0-2 Flowcytometry DHSS/
Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 2.42 10^3/µI 2-7 Calculated
Absolute Lymphocyte Count 1.48 10^3/µI 1-3 Calculated
Absolute Monocyte Count 0.4 10^3/µI 0.2-1 Calculated
Absolute Eosinophil Count 0.18 10^3/µI 0.02-0.5 Calculated
Absolute Basophil Count 0 10^3/µI 0.02-0.1 Calculated
Platelet Count 315 10^3/µI 150-410 Impedence Variation
/Microscopy
MPV 8.4 fl 6.5 - 12 Calculated

Page 2 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133800 / 8360891 Sample Receive Date : 07/Nov/2023 12:45PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 07/Nov/2023 03:19PM

HAEMATOLOGY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

PDW 13 fl 9 - 17 Calculated

Comment:

As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts
are additionally being reported as absolute numbers of each cell in per unit volume of blood.

Page 3 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133800 / 8360891 Sample Receive Date : 07/Nov/2023 12:45PM
Referred By : Dr. Report Status : Final Report
Sample Type : EDTA Report Date : 07/Nov/2023 03:12PM

HAEMATOLOGY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Erythrocyte Sedimentation Rate 28 mm/hr 0-10 Capillary Photometry

Comment:

ESR provides an index of progress of the disease and is widely used as an indicator of inflammation, infection, trauma, or
malignant diseases. Changes are more significant than a single abnormal test
It is specifically indicated to monitor the course or response to the treatment of diseases like rheumatoid arthritis,
tuberculosis bacterial endocarditis ,acute rheumatic fever ,Hodgkins disease,temporal arthritis , and systemic lupus
erythematosis; and to diagnose and monitor giant cell arteritis and polymyalgia rheumatica.
An elevated ESR may also be associated with many other conditions, including autoimmune disease, anemia,
infection,malignancy,pregnancy, multiple myeloma, menstruation, and hypothyroidism.
Although a normal ESR cannot be taken to exclude the presence of organic disease, its rate is dependent on various
physiologic and pathologic factors.
The most important component influencing ESR is the composition of plasma. High level of C-Reactive Protein, fibrinogen,
haptoglobin, alpha-1antitrypsin, ceruloplasmin and immunoglobulins causes the elevation of Erythrocyte Sedimentation
Rate.
Drugs that may cause increase ESR levels include: dextran, methyldopa, oral contraceptives, penicillamine, procainamide,
theophylline, and Vitamin A. Drugs that may cause decrease levels include: aspirin, cortisone, and quinine

"Test conducted on Whole Blood - EDTA "

Page 4 of 16
 PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133795 / 8360891 Sample Receive Date : 07/Nov/2023 12:48PM
Referred By : Dr. Report Status : Final Report
Sample Type : Fluoride Plasma F Report Date : 07/Nov/2023 02:38PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Glucose - Fasting
Glucose - Fasting 97 mg/dL 70-100 Hexokinase

Comment:

Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
HbA1c Less than 7%

Page 5 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:50PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 198 mg/dL Low (desirable): < 200 Enzymatic
mg/dL
Moderate (borderline)
200–239 mg/dL
High: >/= 240 mg/dL
Triglycerides 95 mg/dL Normal: <150, GPO, Trinder without
Borderline: 150 - 199, serum blank
High:200-499,
Very High>=500
Cholesterol - HDL 42 mg/dL Undesirable/high risk Elimination/catalase
<=40mg/dL
Desirable/low
risk>=60mg/dl
Cholesterol - LDL 138 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 19 mg/dL <30 Calculated
Cholesterol : HDL Cholesterol 4.8 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 3.31 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 156 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,

Page 6 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:50PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Very High: >= 220

Comment:
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130

Page 7 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:50PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

Page 8 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:50PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Liver Function Test

Bilirubin-Total 0.80 mg/dL 0.3 – 1.2 Vanadate oxidation
Bilirubin-Direct 0.25 mg/dL 0.0-0.3 Vanadate oxidation
Bilirubin-Indirect 0.55 mg/dL 0.2-0.8 Calculated
Protein, Total 7.40 g/dL 5.7–8.2 Biuret
Albumin 4.40 g/dL 3.2-4.8 BCG Dye Binding
Globulin 3.0 g/dl 2.1-3.9 Calculated
A/G Ratio 1.47 Ratio 0.8 - 2.1 Calculated
Aspartate Transaminase (SGOT) 35 U/L <34 U/L Modified IFCC
Alanine Transaminase (SGPT) 35 U/L 10-49 Modified IFCC
SGOT/SGPT 1.00 Ratio <1 Calculated
Alkaline Phosphatase 86 U/L 45-129 IFCC Standardization
Gamma Glutamyltransferase (GGT) 25 U/L <73 Modified IFCC

Comment:
•LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of the
Existence, Extent and Type of Liver damage. - Acute Hepatocellular damage: ALT & AST levels are sensitive index of
hepatocellular damage - Obstruction to the biliary tract,Cholestasis and blockage of bile flow:1) Serum Total Bilirubin
concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5`-Nucleotidase -
Chronic liver disease: Serum Albumin concentration
•Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous
membranes caused by hyperbilirubinemia.
•Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert’s syndrome,
Crigler-Najjar syndrome
•Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis
•Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas
•In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT concentrations are
elevated even before the clinical signs and symptoms of disease appear.
•ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity.
•Peak values of aminotransferase activity occur between the seventh and twelfth days. Activities then gradually decrease,
reaching normal activities by the third to fifth week. Peak activities bear no relationship to prognosis and may fall with worsening
of the patient's condition.
•Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper
reference limit to four to five times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade of
fibrosis in these patients. Slight or moderate elevations of both AST and ALT activities have been observed after administration
of various medications and chronic hepatic injury such as (1) hemochromatosis, (2) Wilson disease, (3) autoimmune hepatitis, (4)
primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency.
•AST activity also is increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching

Page 9 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:50PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method
concentrations up to eight times the upper reference limit.Slight to moderate AST elevations are noted in hemolytic disease.
•GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease
regardless of cause. Increased concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant drugs,
such as phenytoin and phenobarbital.

Page 10 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:50PM

BIOCHEMISTRY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Kidney Function Test.

Blood Urea Nitrogen 12 mg/dL 9.0-23.0 Urease with GLDH
Urea 25.68 mg/dL 19.26-49.22 Calculated
Creatinine 0.85 mg/dL 0.70-1.30 Kinetic Alkaline Picrate
Uric Acid 5.9 mg/dL 3.5-7.2 Uricase/Peroxidase
Sodium 138 mEq/L 132.0-146.0 Indirect ISE
Potassium 4.93 mEq/L 3.5-5.5 Indirect ISE
Chloride 103.0 mEq/L 99-109 Indirect ISE
BUN/Creatinine Ratio 14.1 Ratio 12:1 - 20:1 Calculated

Comment:
BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of excretion of urea.Blood
urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal
failure (acute or chronic), urinary tract obstruction, dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased
levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets).
Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Urea
diffuses freely into extracellular and intracellular fluid and is ultimately excreted by the kidneys. Increased levels are found in
acute renal failure, chronic glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein
ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting from starvation,
neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary
protein, low-protein/high-carbohydrate diet, malabsorption syndromes, pregnancy, severe liver disease, certain drugs.
Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular
secretion. Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in
acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs, shock, dehydration, congestive heart
failure, diabetes. Decreased levels are found in muscular dystrophy.
BUN/Creatinine ratio (normally 12:1–20:1) is decreased in acute tubular necrosis, advanced liver disease, low protein intake,
and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism.
Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are
seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of body cells
in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell
anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of
parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats, some seafood
and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate antidiuretic hormone (SIADH),
certain drugs.

Page 11 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:41PM

Immunology
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Thyroid Stimulating Hormone - Ultra 2.310 uIU/ml 0.55 - 4.78 CLIA

Sensitive

Comment:

Reference ranges for TSH (μIU/ml) [As per American thyroid

Pregnancy
Association]
1st
0.1-2.5
trimester
2nd
0.2-3.0
trimester
3rd
0.3-3.0
trimester

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection
or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
For the diagnosis of hypothyroidism and hyperthyroidism, sole dependence on TSH should not be done and assay needs
to be interpreted with the clinical condition & other investigations.
Serum TSH level changes significantly in response to even minor changes in thyroid hormones.
Transient increase in TSH level or an abnormal TSH levels can be seen in various nonthyroidal diseases.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.

Page 12 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133798 / 8360891 Sample Receive Date : 07/Nov/2023 12:42PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 07/Nov/2023 04:41PM

Immunology
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

TSH T3 T4 Interpretation
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low
Hypothyroidism

Page 13 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : D6133797 / 8360891 Sample Receive Date : 07/Nov/2023 01:09PM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 07/Nov/2023 07:24PM

CLINICAL PATHOLOGY
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Urine Routine & Microscopy

Colour YELLOW Pale Yellow Manual
Appearance CLEAR Clear Manual
Specific gravity 1.025 1.003 - 1.035 pKa change
pH 6.0 4.6 - 8.0 Double Indicator
Glucose Negative Negative GOD-POD
Protein Negative Negative Protein Error Principle
Ketones Negative Negative Nitroprusside
Blood Negative Negative Peroxidase
Bilirubin Negative Negative Diazonium
Urobilinogen Normal Normal Ehrlich
Leucocyte Esterase Negative Negative Pyrrole
Nitrite Negative Negative P-arsanilic acid
Pus cells 1-2 /hpf 0-5 Microscopy
Red Blood Cells NIL /hpf 0-2 Microscopy
Epithelial cells 1-2 /hpf Few Microscopy
Casts NIL /lpf Nil Microscopy
Crystals NIL Nil Microscopy
Yeast NIL Nil Microscopy
Bacteria NIL Nil Microscopy

Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens

Page 14 of 16
 PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : Z8360891 / 8360891 Sample Receive Date : 01/Jan/0001 12:01AM
Referred By : Dr. Report Status : Final Report
Sample Type : Human Subject Report Date : 07/Nov/2023 01:05PM

CLINICAL WELLNESS
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Blood Pressure (BP)

Blood Pressure 125/91 mm Hg Oscillometric

Comment:
Classification Systolic/Diastolic
Normal BP <130/80
High normal BP systolic BP of 130-139 mm Hg & diastolic of 80-89 mm Hg
High normal/hypertension BP > 140 mm Hg systolic and/or greater than 90 mm Hg diastolic
Hypertension BP of >160 mm Hg systolic and/or greater than 100 mm Hg diastolic

Reference: Hypertension, Ministry of Health & Family Welfare Government of India (2016).
This is measured by a Phlebotomist and the same has been entered.

Body Mass Index (BMI)

Height 172.00 cm
Weight 75 kg
Body Mass Index 25.35 kg/m2 Calculated

Comment:

BMI is defined as a person's weight in kilograms divided by the square of his height in meters (kg/m2).
World Health Organization (WHO) defines overweight and obesity as abnormal or excessive fat accumulation that
presents a risk to health.
Obesity classification according to Asia-Pacific guidelines:

Classification BMI
Under-weight <18.5
Normal 18.5 - 22.9
Overweight 23–24.9
Obese ≥25

Page 15 of 16
PO No :PO1978626010-345

Name : Mr.RAVI GANDHI Client Name : TATA 1MG MUMBAI

Age/Gender : 34/Male Registration Date : 07-Nov-23 12:22 PM
Patient ID : MUM543593 Collection Date : 07/Nov/2023 08:38AM
Barcode ID/Order ID : Z8360891 / 8360891 Sample Receive Date : 01/Jan/0001 12:01AM
Referred By : Dr. Report Status : Final Report
Sample Type : Human Subject Report Date : 07/Nov/2023 01:05PM

CLINICAL WELLNESS
TCS WELLNESS PACKAGE PATHOLOGY HOME VISIT
Test Name Result Unit Bio. Ref. Interval Method

Reference: Asia Pacific Guidelines.

This is calculated by a Phlebotomist and the same has been entered.

*** End Of Report ***

Page 16 of 16
 TATA1mg Labs
NABL certificate
and Scope

THANK YOU
for choosing us as your healthcare partner
Tata 1mg Labs, India's trusted diagnostics lab chain, is serving over a million customers each year across
50+ cities. We offer a broad range of tests through an extensive catalog and cutting-edge technology. Our
commitment to providing high-quality healthcare is supported by 11 state-of-the-art laboratories, ensuring
easy access to our services across the country.

Q Delhi (National Reference Lab) Q Gurgaon Q Mumbai Q Pune Q Kolkata

Q Lucknow Q Ahmadabad Q Bangalore Q Chennai Q Hyderabad Q Dehradun

Our Promise
Hygienic In accordance with Expert team Doctor-verified
sample international norms & of medical reports with 3-step
collection clinical safetystandards professionals review process

Get FREE doctor consultation

on every lab test
Watch how
1A1A@ilto
Consult top doctors we take care of
from the comfort of your home your sample

CLAIM NOW>

Introducing TATA 1mg

Cancer Care Platf Need more help?

One stop for comprehensive cancer assistance
Information on specialty medicines, oncologists in your city, Callon
diagnostic tests, PSPs & more
1800-102-1618
EXPLORE NOW >

Conditions of Laboratory Testing & Reporting:

Test results released pertain to the sample, as received. laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be
clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report may vary
depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal purposes. Please mail
your queries related to test results to Customer Care mall ID [email protected]

Disclaimer: Results re/ate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All lab test
results are subject to clinical interpretation by a qualified medico/ professional. This report cannot be used for any medico-legal purposes. Partial
reproduction of the test results is not permitted. Also, TA TA 1mg Lobs is not responsible for any misinterpretation or misuse of the information. The test
reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be vetted by o qualified doctor only.